Transplantation hépatique pour hépatite chronique B

摘要: Liver transplantation for hepatitis B represents 5-10 % of all liver transplantations performed in Europe. The prognosis after is related to the efficacy prophylaxis HBV graft reinfection. risk reinfection directly viral load at transplantation. with long-term administration anti-HBS immune globulins (HBIG) or monoprophylaxis lamivudine can reduce significantly recurrence mainly patients without active replication. Antivirals such as lamivudine, adefovir, entecavir tenofovir control replication decompensated cirrhosis waiting However, there a breakthrough during nucleo (t) side antiviral treatment. use an alone combination should take into account and resistance. post-transplant therapy HBIG very effective reducing rate less than 10 even In absence transplantation, possibilty discontinue maintenance treatment vaccination evaluation. new therapies (nucleos(t)ide analogues) has dramatically improved graft. current 5-year survival disease 85 %. conclusion, combining prior post-transplantation